Melphalan Tillomed (Melphalan)

Melphalan forms covalent cross‑links between DNA strands, preventing DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells, thereby reducing tumor growth.

The specific dose and schedule of Melphalan Tillomed are determined by the treating physician based on the patient’s diagnosis, disease stage, body surface area and overall health. Only a qualified prescriber can set the appropriate regimen.

Melphalan is classified as potentially harmful to a developing fetus and is generally contraindicated during pregnancy. It is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment. Discuss risks with a healthcare professional.

To request Melphalan Tillomed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Melphalan is a nitrogen‑mustard alkylating agent with a broad spectrum of activity against hematologic and solid tumors. Compared with agents like cyclophosphamide, melphalan often has higher potency but may cause more pronounced bone‑marrow suppression, requiring closer hematologic monitoring.

Melphalan Tillomed should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Follow aseptic techniques when preparing the intravenous solution to maintain sterility.

Melphalan Tillomed is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescribing oncologist and may vary according to the treatment protocol and patient tolerance.

The most serious risks include severe bone‑marrow suppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity, and renal impairment. Patients should be monitored closely for signs of infection, respiratory distress and changes in kidney function.

Melphalan Tillomed is contraindicated in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, those with uncontrolled infections, severe renal or hepatic impairment, and pregnant or breastfeeding women unless the benefits outweigh the risks.